Associated Banc Corp Sells 28,410 Shares of Pfizer Inc. $PFE

Associated Banc Corp lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 14.5% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 167,234 shares of the biopharmaceutical company’s stock after selling 28,410 shares during the quarter. Associated Banc Corp’s holdings in Pfizer were worth $4,054,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PFE. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 2,087 shares during the last quarter. TCW Group Inc. raised its holdings in shares of Pfizer by 5.7% in the first quarter. TCW Group Inc. now owns 84,061 shares of the biopharmaceutical company’s stock worth $2,130,000 after buying an additional 4,523 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Pfizer by 29.9% during the 1st quarter. Mackenzie Financial Corp now owns 844,463 shares of the biopharmaceutical company’s stock worth $21,399,000 after acquiring an additional 194,550 shares during the last quarter. Finally, Norden Group LLC boosted its holdings in Pfizer by 3.4% during the 1st quarter. Norden Group LLC now owns 32,627 shares of the biopharmaceutical company’s stock valued at $827,000 after acquiring an additional 1,065 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Guggenheim raised their price target on shares of Pfizer from $33.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday. UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Citigroup upped their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $28.39.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $25.73 on Wednesday. The firm has a 50 day moving average of $24.91 and a 200 day moving average of $24.54. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $146.26 billion, a price-to-earnings ratio of 13.68, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, November 7th. Pfizer’s payout ratio is 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.